Novartis signs new agreement with BioNTech for COVID-19 vaccine fill and finish

By Rachel Arthur contact

- Last updated on GMT


Related tags: Novartis, COVID-19 vaccine

Novartis has signed a new initial agreement with BioNTech for COVID-19 vaccine manufacturing: with its sterile manufacturing facilities in Ljubljana, Slovenia, to fill at least 24 million doses in 2022.

It follows an earlier supply agreement for the fill and finish of more than 50 million doses in 2021 at the Novartis Stein site in Switzerland, which has been under way since June.

Novartis Technical Operations facility

Under the terms of the new initial agreement announced this morning, Novartis will take bulk mRNA active ingredient from BioNTech and fill this into vials under sterile conditions for shipment back to BioNTech for its distribution.

Novartis plans to transfer the manufacturing process from Stein to its ​Ljubljana site to commence the fill and finish in the first half of 2022. The Novartis Technical Operations facility in Ljubljana is a state-of-the-art aseptic filling operation which currently manufactures and supplies a broad range of aseptic products for Sandoz, a Novartis division.

Pfizer and BioNTech together expect to manufacture around 3 billion doses of their mRNA COVID-19 vaccine in 2021 and expect capacity to rise to 4 billion doses in 2022​: driven by ongoing demand for initial vaccination and booster shots.

Increased capacity will be helped by manufacturing partnerships such as its agreements with Novartis. The European Medicines Agency’s human medicines committee (CHMP) this week approved two new additional manufacturing sites​ for the vaccine in Italy: one in Monza, operated by Patheon Italia S.p.A.; and the other in Anagni, operated by Catalent Anagni S.R.L.

Sites lined up for the future include Biovac's South Africa facility​​​, which will start manufacturing doses in 2022 with capacity for more than 100 million doses a year. Further ahead, BioNTech will establish a fully-integrated mRNA manufacturing facility in Singapore, which is expected to become operational in 2023.

Related news

Show more

Related products

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Fill-Finish Biologics

Fill-Finish Biologics

Curia | 16-May-2022 | Technical / White Paper

The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for...

Related suppliers

Follow us


View more